Date:3/28/2011

search, Lincoln, CA

Telephone: 916-434-8230

2.
Northern California Research, Sacramento, CA

Telephone: 916-484-0500

IRB approval has been sought and is expected soon at a third site:3.
Alta Bates, Jordan Research and Education Institute, Berkeley, CA

Telephone: 510-849-0417 extension 12

About MenerbaMenerba is an oral drug candidate designed for the safe, effective treatment of vasomotor symptoms (hot flashes) associated with menopause, which is manufactured from botanical sources. Menerba is an estrogen receptor beta (ER-b) selective drug, developed as an alternative to the products currently on the market which have been shown to increase the risk for breast and uterine cancers. It has been shown that the increased risk of breast and uterine cancers is associated with activation of estrogen receptor alpha (ER-a) and that activation of estrogen receptor beta (ER-b) blocks the growth promoting effects on breast cancer cells. The active ingredients in Menerba are derived from botanicals with centuries of recorded safe, effective use in traditional Chinese medicine (TCM). Bionovo recognizes the opportunity to commercialize a product that would be as effective as hormone therapy, without the health risks. Menerba has completed a Phase 2 trial with positive results for efficacy and has been evaluated by an independent Data and Safety Monitoring Board and passed through a standard two-round examination for safety. Menerba also has been shown in animal studies to prevent the proliferation of breast cancer and to have a beneficial effect on osteoporosis, though this has not yet been studied in humans.

About Bionovo, Inc.Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual reven
'/>"/>

SOURCE Bionovo, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Bionovo Announces 2010 Highlights and Year-End Financial Results
2. Bionovo, Inc. to Announce Fourth Quarter Fiscal Year 2010 Financial Results on Tuesday, March 15, 2011
3. Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference
4. Bionovo Announces 2011 Plan of Action on MF101 (Menerba™)
5. Bionovo Announces Pricing of Follow-on Offering of Common Stock and Warrants
6. Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors
7. Bionovo Releases FDA-Approved Clinical Development Plan for Menerba
8. Bionovo Announces Publication Describing Estrogen Receptor Beta Cancer Prevention Mechanism
9. Bionovo Announces Third Quarter 2010 Highlights and Financial Results
10. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2010 Financial Results on Thursday, November 11, 2010
11. Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions